BeiGene starts Phase III of anti-PD-1 mAb in HCC

BeiGene Ltd. (NASDAQ:BGNE) said it began in December 2017 an open-label, international Phase III trial to compare tislelizumab (BGB-A317) to Nexavar sorafenib from

Read the full 230 word article

User Sign In